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Abstract
Background: Fully efficient vaccines against malaria pre-erythrocytic stage are still lacking. The objective of this dose/
adjuvant-finding study was to evaluate the safety, reactogenicity and immunogenicity of a vaccine candidate based on a
peptide spanning the C-terminal region of Plasmodium falciparum circumsporozoite protein (PfCS102) in malaria naive
adults.
Methodology and Principal Findings: Thirty-six healthy malaria-naive adults were randomly distributed into three dose
blocks (10, 30 and 100 mg) and vaccinated with PfCS102 in combination with either Montanide ISA 720 or GSK proprietary
Adjuvant System AS02A at days 0, 60, and 180. Primary end-point (safety and reactogenicity) was based on the frequency of
adverse events (AE) and of abnormal biological safety tests; secondary-end point (immunogenicity) on P. falciparum specific
cell-mediated immunity and antibody response before and after immunization. The two adjuvant formulations were well
tolerated and their safety profile was good. Most AEs were local and, when systemic, involved mainly fatigue and headache.
Half the volunteers in AS02A groups experienced severe AEs (mainly erythema). After the third injection, 34 of 35 volunteers
developed anti-PfCS102 and anti-sporozoite antibodies, and 28 of 35 demonstrated T-cell proliferative responses and IFN-c
production. Five of 22 HLA-A2 and HLA-A3 volunteers displayed PfCS102 specific IFN-c secreting CD8+ T cell responses.
Responses were only marginally boosted after the 3rd vaccination and remained stable for 6 months. For both adjuvants, the
dose of 10 mg was less immunogenic in comparison to 30 and 100 mg that induced similar responses. AS02A formulations
with 30 mg or 100 mg PfCS102 induced about 10-folds higher antibody and IFN-c responses than Montanide formulations.
Conclusions/Significance: PfCS102 peptide was safe and highly immunogenic, allowing the design of more advanced trials
to test its potential for protection. Two or three immunizations with a dose of 30 mg formulated with AS02A appeared the
most appropriate choice for such studies.
Trial Registration: Swissmedic.ch 2002 DR 1227
Citation: Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, et al. (2009) The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102
as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial. PLoS ONE 4(10): e7304. doi:10.1371/journal.pone.0007304
Editor: David Joseph Diemert, Sabin Vaccine Institute, United States of America
Received March 27, 2009; Accepted August 25, 2009; Published October 2, 2009
Copyright: ! 2009 Audran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was sponsored by RMF Dictagene SA, Epalinges, Switzerland and received funds from WHO and the Stanley Thomas Johnson Foundation,
Bern, Switzerland. Past employees of the study sponsors (H. E. Blythman and C. Reymond) were involved in clinical monitoring, study design, and analysis, and
reviewing. The funders had no role in data collection or decision to publish. FS, RA, FL and BG had access to all data reported in this work, and FS as PI acts as
guarantor for the paper.
Competing Interests: HE Blythman and Christophe Reymond were employees of RMF Dictagene at the time of the study was performed. Since this time, RMF
Dictagene went bankrupt. O.Ofori-Anyinam was an employee of GlaxoSmithKline Biologicals. No other conflict of interest relevant to this article was reported.
* E-mail: Francois.Spertini@chuv.ch
Introduction
P. falciparum induced malaria is a major cause of disease and
death in tropical areas. The difficulty to obtain a protective
malaria vaccine is largely related to the genetic complexity of the
parasite, to its metamorphosis across several life stages within the
human host and to its strategies, acquired with evolution, to escape
host immune response. The hope for an efficient vaccine is based
on the observation that natural exposure to repeated infections
leads to some degree of immune protection and that humans can
acquire a complete pre-erythrocytic protection after repeated
immunization with irradiated sporozoites (reviewed in [1]). Studies
performed in animals and in human volunteers have demonstrated
that the anti-sporozoite protection depends on both humoral and
cell-mediated immune (CMI) response [2]. Facing the difficulties
of the large-scale production of an attenuated sporozoite based
vaccine [3], subunit candidates were selected on the basis of the
protective immune response obtained with irradiated sporozoites.
The circumsporozoite protein (CSP), which is abundant at the cell
surface of Plasmodium sporozoite, appeared to play a crucial role in
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preclinical and clinical models of protection [4] implicating
humoral [5], CD4+ and CD8+ T cell response [6–14].
Different CSP-derived vaccine constructs have been evaluated
in clinical trials, including synthetic peptides, which have the
advantage to be rapidly obtainable at high degree of purity and to
have absent intrinsic toxicity in clinical grade batches. In
preclinical studies, a long synthetic peptide (LSP), encoding the
C-terminal 282–383 region of CSP, was found to be highly
immunogenic and protective [15–18]. In addition, individuals
living in malaria-endemic areas develop high titers of specific
antibodies and a vigorous CMI response to this sequence [19]. A
preliminary Phase I study was completed using a GLP grade Pf
CSP 282–383 batch (PfCS102) [20]. The vaccine was well
tolerated and safe. The humoral immune response induced by
PfCS102 adjuvanted with Montanide was excellent, as well as the
CMI response based on the induction of specific CD8+ T cells and
IFN-c secretion.
In view of these results, in this Phase I study we evaluated the
safety and immunogenicity of PfCS102 LSP synthesized under
GMP conditions, as required for clinical trials, as well as its
combination with two adjuvants, AS02A and Montanide, in six
groups of healthy adult volunteers for three dose levels of LSP.
Methods
Objectives
The objectives of this trial were to investigate the safety and
tolerability of the intra-muscular administration of the PfCS102
LSP, injected in combination with two different adjuvants, as a
candidate malaria vaccine. We determined the occurrence and
severity of vaccine-related adverse events (AE) for each combina-
tion of vaccine (primary objective) in order to define the optimal
antigen-adjuvant combination, i.e. the combination inducing the
highest humoral and CMI response (secondary objective).
Participants
Protocol and supporting CONSORT Checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Volunteers, male and female between 18 and 45 years, were
recruited in the Lausanne area, Switzerland, and examined at the
Centre Hospitalier Universitaire Vaudois, Vaccination and
Immunotherapy Center. Volunteers should not have lived in
endemic areas, were negative for HIV, HBV and HCV antibody
screening, and were excluded when presenting with any acute or
chronic medical conditions, evidence of abnormality in clinical or
laboratory findings, pregnancy, previous history of malaria, or
positive antibody response to PfCS102 by ELISA. During the
study period, volunteers were not authorized to visit or to reside in
a malaria endemic area. Female participants had to take an
adequate contraception. A urinary pregnancy test was done before
injections. After inclusion, participants were tested for HLA locus
A by PCR-SSO (LiPA-HAL-A Update, Innogenetics, Ghent, B)
according to manufacturer’s instruction, in preparation of the
monitoring of PfCS102 specific MHC class I responses in HLA-A2
and -A3 volunteers for whom PfCS epitopes were known.
Ethics Statement
The protocol was approved by the Ethical Review Board of the
Faculty of Biology and Medicine, Lausanne, Switzerland and by
the Swiss Regulatory Agency For Therapeutic Products (Swissme-
dic, #2002 DR 1227); the approvals are available as supporting
information, Approval letters S1 and S2. Before enrolment into
the study, all volunteers gave their written informed consent. A
copy of the consent form is available as supporting document,
Consent form S1. The trial was conducted according to GCP and
the principles of The Declaration of Helsinki.
Vaccine preparation
The vaccine LSP PfCS102 (KNNQGNGQG HNMPNDPNRN
VDENANANSA VKNNNNEEPS DKHIKEYLNK IQNSL-
STEWS PCSVTCGNGI QVRIKPGSAN KPKDELDYAN
DIEKKICKME KCS) encompassed the C-terminal non-repeat
region 282-383 of CSP of the P.falciparum strain NF54. The peptide
was synthesized, purified, bottled and lyophilized according to
GMP procedures (batch 01FS019, RMF Dictagene SA, Epalinges,
Switzerland) and tested for stability and toxicity (sterility, endotoxin
content, apyrogenicity) as well as for immunogenicity in mice when
formulated with adjuvants cited below.
Peptide-adjuvant combinations were prepared under sterile
conditions within four hours of injection. PfCS102 as a lyophilized
powder was dissolved at room temperature either (A) in 180 ml of
sterile NaCl 0.9% (Bichsel AG, Interlaken, Switzerland), mixed
with 420 ml of Montanide ISA-720 (Seppic Paris, France) and
passed at least 10 times through a 21G needle to form a stable
(3/7, w/w) water-in-oil emulsion according to manufacturer’s
instructions, or (B) directly in 600 ml of GSK proprietary Adjuvant
System AS02A (oil-in-water emulsion with the immunostimulants
monophosphoryl lipid A (MPL; GSKBio NA, WA,USA) and
Quillaja saponaria fraction 21 (QS21; Antigenics, New York, NY,
USA). For 10 and 30 mg doses, peptide was first diluted in NaCl
0.9% or in AS02A.
Whatever the peptide dose (10, 30 and 100 mg), the final
quantity of adjuvant Montanide ISA-700 or AS02A for each
formulation was constant.
Phase I study design
This study was designed as a randomized, double-blind, dose-
ranging study to assess the safety and immunogenicity of three
vaccine dose regimens combined with two different adjuvants. Six
groups of 6 subjects received 3 injections at days 0, 60 and 180, of
10, 30 or 100 mg of peptide in Montanide ISA 720 (groups M10,
M30, M100 respectively) or in AS02A (groups A10, A30 and
A100). The vaccine was delivered as a 500 ml injection
intramuscularly in the deltoid region of alternating arm.
At days 0, 30, 60, 75, 180, 195 and 360, whole blood samples
were collected on citrate as anticoagulant (Vacutainer CPT, BD,
Basel, Switzerland); peripheral blood mononuclear cells (PBMC)
were separated on a density gradient, used fresh in proliferation
assay or stored in liquid nitrogen for other analysis. Plasma was
collected after the first centrifugation.
Assessment of safety and tolerability
Volunteers were observed for one hour after each immunization
and returned for a follow-up visit 2 and 30 d after the first
injection, 2 and 15 d after the second injection and 2, 15, 180, and
360 d after the third injection. Safety parameters included clinical
observations and laboratory measurements. Solicited local and
general AEs were monitored at each follow-up visit and self-
reported in personal diaries from day 0 to 3 after each injection.
Unsolicited local and general AEs were monitored up to 30 d after
injection in diary cards, but had to be reported anytime during the
whole trial at each visit. Diary cards were collected at days 30, 75
and 195 and furthermore a phone call was made by the
investigator 30 d after the 2nd and 3rd injection to obtain an
update on new or previously ongoing AEs. Subjects were
requested to come to the site for unresolved AEs related to the
vaccination Serious AEs were recorded throughout the study.
Solicited local AE included pain, skin erythema, pruritus,
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induration (including swelling) and functional limitation of the
arm. Solicited systemic AEs included fatigue, headache, fever,
arthralgia, myalgia, gastro-intestinal disorders, exanthema, urti-
caria, dyspnea, fainting, dizziness, sweating and palpitations. AEs
(solicited and unsolicited) were graded from 0 to 3 (grade 0: no
impairment; grade 1 (mild): easily tolerated; grade 2 (moderate):
interference with daily activity; grade 3 (severe): prevention of
daily activities), except for erythema and induration, which were
graded on the size of the lesion measured by the investigator 48 h
after injection (grade 1 (mild): 1–19 mm; grade 2 (moderate): 20–
49 mm; grade 3 (severe): $50 mm) and fever, which was graded
on a scale of axillary temperature (grade 0: ,37,5uC; grade 1:
37.5–37.9uC; grade 2: 38–38.9uC;. grade 3: $39uC). Subjects
were withdrawn from receiving further vaccinations if they were
presenting a local induration after the 1st or the 2nd injection
measuring $12 cm in diameter. Haematology (hemoglobin,
hematocrit, white blood cell count, platelet count) and blood
chemistry parameters (blood urea nitrogen, serum creatinine,
alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase) were evaluated at screening, 30 d after the first
injection, 15 d after the second injection and 15 and 180 d after
the third injection.
Peptides
In proliferation assay, three overlapping peptides spanning
100% of PfCS102 were used to identify most immunogenic
regions: PfCS 282–318 (KNNQGNGQG HNMPNDPNRN
VDENANANSA VKNNNNEE), PfCS 319–383 (PS DKHI-
KEYLNK IQNSLSTEWS PCSVTCGNGI QVRIKPGSAN
KPKDELDYAN DIEKKICKME KCS) and PfCS 310–340 (A
VKNNNNEEPS DKHIKEYLNK IQNSLSTEWS). MHC-class I
(MHC-I) restricted cytotoxic T lymphocyte (CTL) epitopes were
used in CD8+ T cell stimulation assays and prior to intracellular
cell staining (ICS) (HLA-A2 specific epitopes: PfCS 327–335
(YLNKIQNSL), PfCS 292–301 (NMPNDPNRNV); HLA-A3
specific epitopes: PfCS 344–342 (VTCGNGIQVR), PfCS 353–
361 (RIKPGSANK)) as well as peptide controls FLU MP 58–66,
(GILGFVFTL), CMV pp65 495–503 (NLVPMVATV) and FLU
NP 265–273 (ILRGSVAHK).
Antibody responses
Anti-PfCS102 antibodies were measured in plasma samples by
ELISA as previously described [20]. Results were expressed as
arbitrary units (U/ml) according to a linear standard curve,
100 U/ml corresponding to a titer of 1/12800. ELISA was
performed blind by the lab technician, then validated and
interpreted blind by lab technician and scientific supervisor. The
presence of antibody recognizing P. falciparum CS protein in its
native configuration was determined by an indirect IFA method
[20] using NF54 parasites fixed on 10-well slides, 5000
sporozoites/well (kindly provided by C. C. Hermsen, NL-
Nijmegen). For IFA, data was based on the evaluation of two
blinded examiners. Results were expressed as geometric means of
titrations defined as the last plasma dilution giving a positive
signal. A response above the baseline, defined as the mean
response of pre-immune sera + 3SD, was considered positive.
T cell proliferation assay and cytokine measurements
PBMC were stimulated with PfCS102 (1.2, 6 and 30 mg/ml) or
with tetanus toxoid (TT, 10 mg/ml) or phytohemagglutinin (PHA,
5 mg/ml) as controls, as previously described [21]. Production of
IFN-c and IL-10 in supernatants of five-day proliferation cultures
was measured by ELISA (Elipair, Diaclone, France), following
manufacturer’s instructions and expressed as pg/ml. Experimental
median lower limits of detection of IFN-c, IL-10 were 0.74,
0.45 pg/ml respectively. The specific activity of IFN-c kit standard
was titrated against NIBSC IFN-c European standard and was set
at 3.61 IU for one ng IFN-c. A response above the baseline,
defined as the mean response of pre-immune cell sample
proliferation + 3SD, was considered positive.
Antigen-specific CD8 T cell detection by long-term
ELISPOT
Cryopreserved PBMC from HLA-A2 volunteers collected before
the first immunization and after the second and the third
immunization were thawed simultaneously. CD8+ T cells were
purified by magnetic cell sorting (Miltenyi Biotec, D-Bergish-
Glabach) and cultured in the presence of 1 mMCTL peptides (PfCS
or controls) and irradiated autologous CD82 cells. On days 9 to 12
of culture, the frequency of antigen specific CD8+ T cell activity was
evaluated by IFN-c ELISPOT as described [7]. Spots were counted
using a computerized system (BioSys GmbH, D-Karben).
Intracellular cytokine staining
The frequency of PfCS102 specific CD4+ or CD8+ T cells was
evaluated by ICS using PBMC of HLA-A2 and/or HLA-A3
volunteers. Pre- and post-immunization PBMC were tested
simultaneously. PBMC (66106 cells/ml) in culture medium were
stimulated for 18 to 20 hours with peptides (PfCS102, 10 mg/ml,
plus HLA-A2 and/or HLA-A3 CTL peptides, 5 mg/ml each) in
the presence of brefeldin A (10 mg/ml, Sigma) during the last four
hours of culture. Unstimulated or SEB (3 mg/ml) stimulated cells
served as controls. To detect activated cells, PBMC were fixed
(FACS lysing buffer, BD), permeabilized (Perm 2, BD) and stained
with anti-IFN-c, -FITC (clone B27), anti-CD4-PerCP-Cy5 (clone
SK3) from BD and anti-CD8-RPE (clone DK25, Dako, DK-
Glostrup) antibodies. Additional analysis of CD8+ cell subsets were
determined by staining with anti-IFN-c, -FITC, anti-CD3-PerCP-
Cy5 (clone B27), anti-CD56-APC (clone B159) (BD), anti-CD8-
RPE (Dako) and anti-CD16-APC (clone 3G8, Serotec). Frequency
of IFN-c secreting lymphocytes in the selected populations was
expressed using the formula: (% IFN-c positive cells in stimulated
cells – % IFN-c positive cells in unstimulated cells). A response
above the baseline, defined as the mean frequency of pre-immune
cell samples + 3SD, was considered positive.
Sample size
This phase I study was designed as a double blind study to
evaluate safety and immunogenicity in a descriptive per total
vaccinated subjects’ analysis. Sample size was thus not defined on
the power of the statistical analysis. However a number of 18
subjects in stratification per adjuvant and 12 subjects in
stratification per peptide doses were estimated reasonably large
for non-parametric statistical analysis.
Randomization
Subjects enrolled by the clinical investigator were randomized
by the statistician per antigen dose, by blocks of 12 subjects, 6 (3
males, 3 females) to each adjuvant cohort. Immediately after
screening and recruitment, the statistician provided randomization
lists to the pharmacist in charge of vaccine preparation and
randomization envelopes to the principal investigator. Vaccina-
tions started with the 10 mg block. After review of safety data
collected for at least 21 days between dose block, the 30 mg block
was vaccinated and finally the 100 mg block. One withdrawal that
occurred before the 2nd injection was replaced with a subject of the
same gender from the list of screened volunteers.
PfCS102 Malaria Vaccine
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Blinding
Study participants and investigators who assessed outcomes
were blinded to vaccine adjuvant assignment. The trial could not
be blind for peptide dose because of the dose-escalating design.
Vaccines were prepared by a pharmacist team who had no contact
with participants. Because of the difference in visual aspect and in
viscosity between adjuvants, a nurse performed the injections in a
separate room, in the absence of the clinical investigator. Study
codes were broken after study completion.
Statistical evaluation
Statistical analysis of clinical response (safety and reactogenicity)
was descriptive and per total vaccinated subjects. When indicated,
two-sided statistical tests were performed regarded as exploratory.
Differences between adjuvant or dose groups were analyzed by
Fisher’s exact test for safety and reactogenicity data (numbers of
AEs). For immunological data, comparisons of adjuvant groups
were performed using a Kruskal-Wallis Rank-Sum test on the log
of the ratio of the ‘‘per time’’ values on those at D0 (SAS software).
Other comparisons of immunological data including CD8+ and
CD4+ T cell responses were calculated using non parametric
Wilcoxon or Mann-Whitney t tests for paired within-group and
between-groups comparisons respectively (GraphPad Prism soft-
ware). Data were considered significant when p was ,0.05.
Results
Participant flow chart (fig. 1)
At the screening visit, 52 volunteers were examined and
subsequently 15 were immediately excluded: in 8 cases for
abnormalities in the clinical safety tests, in 3 cases for positive
anti-PfCS102 antibodies, in 1 case for consent withdrawal, in 2
cases for recent travel in a malaria endemic country, and in 1 case
for abnormal cardiovascular physical exam. Globally, 37 healthy
adults were randomized. One volunteer from group M10 was
withdrawn after the first injection for a non vaccine related severe
adverse event (AE) and was replaced. Thirty-six volunteers
received 2 injections. Thirty-five of them received the three
scheduled injections. The study report includes clinical and
immunological data from 37 volunteers (19 in the Montanide
ISA 720 adjuvant group and 18 in the AS02A adjuvant group) up
to visit 12 (day 540).
Recruitment
Recruitment and enrollment occurred from December 2nd,
2002 to May 20th, 2003. Study duration was 18 months and the
last visit occurred on November 24th, 2004.
Baseline data
Baseline safety laboratory values were all within the normal
range (not shown). There was no imbalance between age, sex and
baseline clinical safety tests at enrolment between the various
groups (Table 1).
Assessment of safety and tolerability
Occurrences of local and systemic reactions imputable to
vaccine after each injection are described in Table 2 and 3.
Solicited AE
AEs were mainly local. No local AE considered as unacceptable
(induration .12 cm in diameter) occurred in any group. After the
first injection, a higher number of AEs occurred in the AS02A (A)
adjuvant group than in the Montanide ISA 720 (M) group (17/18
vs 13/19 respectively). This tendency was significant for pain
(p=0.042), erythema (p=0.0188), and functional limitation
(p=0.0009). The same trend was observed when intensity of all
adverse reactions was considered (6/18 grade 3 AEs in A group vs
1/19 in M group). Similarly, after the second and third injection,
there was a significantly higher occurrence of erythema (p=0.0275
and 0.0045 respectively) and grade 3 AEs (11/18 in A group vs 3/
18 in M group (p=0.0153), and 10/18 in A group vs 0/17 in M
one respectively (p=0.0003)). Most severe local AEs (n = 47)
resolved within 48 h (23/47), others within 72 h (13/47), within
96 h (6/47) and .96 h (5/47) and consisted in majority (28/47) in
erythema. Besides functional limitation which increased together
with dose increase, the frequency of other AE did not appear to be
affected by peptide dose after any of the three injections.
Overall, systemic adverse reactions were dominated by fatigue
(n=45) and headache (n=31), followed by myalgia (n=15) and
arthralgia (n=13), and tended to be more frequent in the AS02A
group (n=34) than in the Montanide ISA 720 group (n=23). After
the first injection, 6 volunteers in the A group presented with myalgia,
but none in the M group (p=0.008). After the second injection, there
was not much difference between adjuvant groups, but after the third
injection, frequency of fatigue and arthralgia was higher in the A
group than in the M group (11/18 in A, 3/17 in M and, 5/18 in A
and 0/17 in M respectively). There was a slight trend towards an
increase in the frequency of systemic AE with increasing peptide dose
but this was statistically significant only for arthralgia (p=0.0455).
Unsolicited AE
Only ‘‘probably vaccine related’’ AEs were reported. They
started during the 4-day follow-up after injection, were mostly
systemic and consisted in adenopathies (n = 2), shivers (n = 4),
pharyngitis (n = 1) and insomnia (n = 1). All were associated with,
at least, fatigue, headache, myalgia, local pain and functional
limitation, and all occurred in AS02A groups.
Serious and unexpected AE
A single severe AE (5 minute episode of palpitations) occurred
4 hours after the first injection during physical stress. On the basis
of the electrocardiogram, the volunteer was suspected of a short
PQ syndrome and referred to a cardiologist for follow-up. The AE
was considered as unrelated to the vaccine but led to volunteer
withdrawal from further injections. Three serious adverse events
occurred between day 195 and day 540; none of them were
considered vaccine-related: in A10 group, a car accident with fatal
issue at day 241, and in M10 group, a voluntary interruption of
pregnancy (14 months after the 2nd vaccination, 3rd injection was
not performed) and the surgical removal of a sacrococcygeal
dermoid cyst at day 384.
Laboratory parameters
Hematology as well as blood chemistry test results performed during
the injection and follow-up periods were within the normal range,
apart from one case of mild alkaline phosphatase increase above the
normal range (36–108 U/l), at days 75, 195 and 360 (121, 129,
150 U/l, respectively), not related to clinically significant abnormality.
The volunteer was later referred to his general practitioner.
Anti-PfCS102 antibody response
Two weeks after the second and the third injection, 97% of
immunized volunteers (35/36 and 34/35 respectively) produced
antibodies against PfCS102 above the baseline (2.9 U/ml)
(medians and quartiles of all responses: 559 U/ml [237.5;
1162.9] and 695.9 U/ml [262.8; 3047.8] respectively) (Figure 2).
PfCS102 Malaria Vaccine
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At day 360, 94% (32/34) of volunteers still displayed a positive
response although of decreasing intensity (median = 157.9 U/ml
[39.0; 636.6]. The level of response was largely higher than the
response obtained in the preliminary PfCS102 study (max-
imum163 U/ml, titer of 25600) [20] or than those observed in
endemic area (median 17.8 U/ml [6.1; 55.5], n = 6). Frequencies
of responders were similar among all six groups. Nevertheless,
after the 2nd and the 3rd immunization, volunteers who received
Figure 1. Study flow chart. Design of the Phase I, double-blind, dose-ranging study of 3 vaccine dosing regimens combined to two different
adjuvants AS02A and Montanide ISA 720. For each dose, volunteers were randomized by blocks of 12, with 6 individuals per adjuvant. Volunteers
were seen 2 and 30 d after the first injection, 2 and 15 d after the second injection and 2, 15, 180, and 360 d after the third injection. A phone call was
addressed to all volunteers at d 30 after the 2nd and 3rd injection.
doi:10.1371/journal.pone.0007304.g001
PfCS102 Malaria Vaccine
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AS02A developed the highest levels of anti-PfCS102 antibodies
without differences between the 30 mg and 100 mg doses, but a
significantly lower response with the 10 mg dose. In contrast, no
dose effect was observed with Montanide ISA 720. Overall,
pooling results of doses 30 mg and 100 mg, antibody levels were at
each time-points higher in the A group than in the M group, and
significant at days 180, 195, 360 (p,0.004, Kruskal-Wallis Rank-
Sum test). At day 360, levels of antibody responses were at least
one log higher in groups immunized with 30 mg or 100 mg
PfCS102 formulated with AS02A than with Montanide ISA 720
(p=0.0065 and 0.0039, respectively, Kruskal-Wallis Rank-Sum
test).
Anti-sporozoite responses
At day 0, none of the volunteers (n = 37) displayed antibodies
specific for P. falciparum sporozoites (median titer = 100 (range 100
to 141) (Figure 3). Anti-sporozoite responses with titers $200 were
considered positive. After the second injection, at day 75, 94%
(34/36) of volunteers developed a positive anti-parasite response
with a median titer of 800 (quartiles 400–3408) (geometric mean
titer: 1199), and after the third injection, 97% (34/35) (median
titre: 3200, quartiles 683–15451; geometric mean titer: 2956).
Whatever the adjuvant, the lowest responses were associated with
the 10 mg PfCS102 dose. Injections with the 30 mg and 100 mg
doses ended up with the same level of responses, as observed above
for anti-PfCS102 responses measures by ELISA. The 3rd injection
did not improve significantly the responses obtained after the second
immunization, except for group M100 (p=0.0312, Wilcoxon’s test).
AS02A formulations elicited significantly higher responses (10-fold
increase) than Montanide ISA 720 using a dose of 30 mg (p=0.0011
at D75, p,0.0001 at D195) or 100 mg of peptide (p=0.0189 at D75,
p,0.0001 at D195, Kruskal-Wallis Rank-Sum test).
T cell proliferation
The first immunization with at least 30 mg PfCS102 induced
significant responses that were boosted by the 2nd immuniza-
Table 1. Characteristics of participants in various immunization groups.
Groups n total n female n HLA-A2 and/or -A3 Age in years mean (95% CI)
10 mg PfCS102 in AS02A 6 3 3 30.2 (8.4)
30 mg PfCS102 in AS02A 6 3 3 29.0 (4.1)
100 mg PfCS102 in AS02A 6 3 3 25.7 (3.2)
10 mg PfCS102 in M ISA 720 7 4 4 25.0 (5.5)
30 mg PfCS102 in M ISA 720 6 3 4 28.4 (5.8)
100 mg PfCS102 in M ISA 720 6 3 5 30.8 (7.5)
doi:10.1371/journal.pone.0007304.t001
Table 2. Local adverse events during the 4-day follow-up after each immunization.
Group
Any
symptom Pain Erythema Pruritus Induration
Functional
limitation
Any
Gr.3
Adjuvant PfCS dose (mg) n Overall (Gr.3) Overall (Gr.3) Overall (Gr.3) Overall (Gr.3) Overall (Gr. 3)
Injection 1 A 10 6 6 6 (1) 3 (3) 1 (0) 4 (1) 4 (1) 3
30 6 6 6 (0) 2 (2) 1 (0) 3 (1) 5 (0) 1
100 6 5 5 (0) 2 (2) 1 (0) 1 (0) 5 (0) 2
M 10 7 5 4 (0) 1 (1) 2 (0) 3 (0) 0 (0) 1
30 6 4 4 (0) 0 (0) 0 (0) 0 (0) 2 (0) 0
100 6 4 4 (0) 0 (0) 0 (0) 1 (0) 2 (0) 0
Injection 2 A 10 6 6 6 (1) 4 (4) 1 (0) 2 (1) 4 (0) 4
30 6 6 6 (0) 5 (3) 1 (0) 5 (2) 3 (1) 4
100 6 6 6 (1) 2 (2) 1 (0) 3 (1) 5 (0) 3
M 10 6 5 4 (1) 2 (0) 0 (0) 4 (0) 2 (0) 1
30 6 5 5 (0) 2 (0) 1 (0) 1 (0) 3 (0) 0
100 6 5 5 (1) 2 (2) 0 (0) 1 (0) 3 (1) 2
Injection 3 A 10 6 6 5 (0) 3 (3) 0 (0) 1 (1) 3 (0) 3
30 6 6 6 (0) 3 (3) 1 (0) 2 (2) 4 (0) 3
100 6 6 6 (0) 5 (4) 1 (0) 3 (1) 6 (0) 4
M 10 5 5 4 (0) 1 (0) 0 (0) 2 (0) 1 (0) 0
30 6 4 4 (0) 1 (0) 1 (0) 1 (0) 1 (0) 0
100 6 5 4 (0) 0 (0) 0 (0) 2 (0) 4 (0) 0
Data are numbers of participants presenting with symptoms. n: number of participants per analysis group. M: Montanide ISA 720. A: AS02A. Gr.3: grade 3.
doi:10.1371/journal.pone.0007304.t002
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Figure 2. Time course of anti-PfCS102 antibody response upon PfCS102 immunization. Anti-PfCS102 antibodies were measured in plasma
samples by ELISA. Results are expressed as individual data in U/ml for each immunization group, with quartiles. Arrows indicate the times of vaccination.
doi:10.1371/journal.pone.0007304.g002
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Figure 3. Time-course of anti-Plasmodium falciparum antibody response upon PfCS102 immunization. Anti-parasite antibodies were
measured in plasma samples by immunofluorescence. Results are expressed as individual titers for each immunization group, with quartiles. Arrows
indicate the times of vaccination.
doi:10.1371/journal.pone.0007304.g003
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tion, in AS02A groups, but not by the third immunization
(Figure 4). After the 2nd and 3rd immunization, the intensity of
the response (median SI: 5.4 (quartiles 2.5 and 9.0)) increased
above the baseline (SI = 1.64) in 32 out of 36 volunteers (89%
responders), 15/18 and 15/18 at D75 and, 16/18 and 12/17 at
D195 in AS02A and Montanide ISA 720 groups respectively.
The dose of 30 mg was sufficient to induce maximal responses.
In term of frequency of responders, there was no difference
between the two adjuvants. However, responses obtained after
the second immunization with the dose of 100 mg formulated
with AS02A were stronger than with Montanide ISA 720
(p= 0.026, Mann-Whitney’s test). Six months after the last
immunization (day 360), 26 out of 34 volunteers were still
responders. For all volunteers, proliferative responses to the
shorter CS 310–340 and 310–383 peptides were comparable to
those obtained with PfCS102, the CS 282–318 inducing only
weak responses.
IFN-c response
After two immunizations, the level of the IFN-c response in
PBMC cultures (median and quartiles: 1630 pg/ml (499;8549,
n = 36) increased above baseline (84.7 pg/ml) in 34 out of 36
volunteers (Figure 5). With Montanide ISA 720, significant
responses were already obtained after the first injection, and no
boosting effect was induced by the following injections. Moreover,
there was no dose effect. With AS02A, the dose of 10 mg induced
delayed responses, with only one responder after the first injection,
and two non-responders overall. Whatever the dose, responses
increased after the second injection, but not after the third one.
Combining peptide dose groups for comparison of adjuvants,
AS02A formulations induced 10-fold higher level of responses than
Montanide ISA 720 after the 2nd or the 3rd immunization
(p,0.02, generally p,0.003, Kruskal-Wallis Rank-Sum test). Like
in proliferation assays, CS 310–340 and 310–383 peptides induced
IFN-c responses similar to PfCS102, CS 282–318 inducing only
weak responses Overall, the frequency of volunteers responding by
the production of IFN-c (34 out of 36) was higher than in the
proliferation assay (32 out of 36). However, there was a strong
correlation between T cell proliferation and IFN-c production
(r = 0.8562, p,0.0001 at day 195, r = 0.8282, p,0.0001 at day
75, Spearman’s rank correlation).
IL-10 response
After immunization, the intensities of the IL-10 responses to
PfCS102 increased slightly above the baseline (28.1 pg/ml) in
80% (29/36) of volunteers (median: 33.5 pg/ml, quartiles 15.8
and 77.8) after the second injection. There was no significant
difference between doses or adjuvants, but there was a tendency
towards higher IL-10 levels with the 100 mg dose (data not
shown).
Antigen specific CD4+ and CD8+ T cell responses
The frequency of PfCS specific CD4+ and CD8+ T cells was
evaluated by ICS in HLA-A2 and HLA-A3 volunteers (n = 22, 10
volunteers received AS02A, 12 received Montanide ISA 720)
(Table 1). Overall, vaccination induced an increase in the
frequency of malaria specific CD4+ and CD8+ lymphocytes in
16 out of 22 volunteers (73%) (Table 4). Frequencies of these
responses were ranging from 0.02% to 0.19% for CD4+ T cells
(median 0.06%) and from 0.02% to 0.53% for CD8+ T cells
(median 0.07%). Responders with frequencies of PfCS specific
CD4+ or CD8+ responses above the baseline (frequencies of
0.038% and 0.086% respectively) represented 36.2% (8/22) of
volunteers (Figure 6, A and B). A further descriptive analysis of the
PfCS102 specific CD8+ lymphocyte subsets in these 8 responders
allowed to discriminate antigen specific NK (CD32 CD8+ CD16/
56+) from NKT cells (CD3+ CD8+ CD16/56+) and from CTL
(CD3+ CD8+ CD16/562). The 8 responders displayed a
frequency of CD8+ NK responses that was about as high as half
the frequency of IFN-c secreting CD8+ lymphocytes (57.6% and
47.8% at day 75 and 195 respectively, data not shown).
Nevertheless, five volunteers showed a marked increase in their
antigen specific CD3+CD8+ T cells with vaccination (Figure 6C),
mostly CTL (80%) and to a lesser extend NKT cells (data not
shown). No distinction between doses or adjuvants could be
drawn. Using the CD8+ cultured ELISPOT, we detected the
presence of PfCS specific IFN-c producing CD8+ T cells in only
one volunteer out of the 14 HLA-A2 selected volunteers. This
responder was one of the 5 responders by ICS described above.
Virus specific CD8+ positive responses were obtained in 13 out of
these 14 volunteers.
Discussion
Interpretation
The present trial compared the safety and immunogenicity of
PfCS102 synthetic peptide 282-383 in its GMP preparation
formulated in three doses with Montanide ISA 720 or AS02A.
The study demonstrated that the two adjuvant formulations were
well tolerated and safe with no evidence of peptide dose effect on
the occurrence of AEs (frequency and type) when administered to
healthy malaria-naive adults. Formulation of PfCS102 with
Montanide ISA 720 was overall better tolerated, especially locally,
grading of erythema and functional limitation was definitely less in
the Montanide ISA 720 group than in the AS02A group.
Immunogenicity results showed that both adjuvant formulations
were able to induce malaria specific responses, although the dose
of 10 mg was less immunogenic in comparison to 30 mg and
100 mg and the humoral and CMI responses were more robust
with AS02A. Immunizations induced marked specific anti-
PfCS102 and anti-sporozoite antibody responses (35/36, at D75,
34/35 at D195) and T cell proliferative responses associated with
IFN-c production (30/36 at D75, 28/35 at D195). Specifically, 5
of 22 HLA-A2 and/or HLA-A3 volunteers developed PfCS102
specific IFN-c secreting CD8+ T cell responses composed in a
major part of CTL and of NKT cells. Humoral and cellular
responses were only partially boosted by the third injection, and
intensity plateaued at the level reached after the second injection,
without substantial difference between 30 mg and 100 mg peptide
doses. Moreover, these responses remained mostly stable at least
for six months after the 3rd injection. The candidate vaccine
formulated with AS02A induced about 10-fold higher antibody
and IFN-c responses than Montanide ISA 720 formulation with
doses of 30 mg or 100 mg. The safety profile and immunogenicity
of the GMP PfCS102 preparation thus confirmed our initial
findings with GLP PfCS102 peptide formulated in Montanide ISA
720.
Pure peptide sequences as well as highly purified proteins have
poor immunostimulatory properties and need to be formulated
with a potent adjuvant to induce a strong adaptive immune
response. Consequently, a given antigen can clearly induce
protective or non protective immunity depending on the adjuvant
used, even at the same antigen dose [22]. The addition of strong
adjuvants in vaccine formulations may be associated with
increased reactogenicity. The direct correlation between reacto-
genicity and immunogenicity was well illustrated in the present
study where frequency and intensity of adverse events as well as
levels of immune responses were higher with AS02A than with
PfCS102 Malaria Vaccine
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Figure 4. Time-course of anti-PfCS102 proliferative T cell response. Proliferative responses were evaluated by 3[H]-thymidine incorporation
by peripheral blood mononuclear cells (PBMC) upon stimulation with antigen. Results are expressed as individual stimulation indices (SI) in each
immunization group with quartiles. Arrows indicate the times of vaccination.
doi:10.1371/journal.pone.0007304.g004
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Figure 5. Time-course of the IFN-c production by PBMC in response to PfCS102. IFN-c was evaluated in the supernatant of stimulated
peripheral blood mononuclear cells (PBMC). Results are expressed as individual IFN-c secretion, expressed in pg/ml for each immunization group,
with quartiles. Arrows indicate the times of vaccination.
doi:10.1371/journal.pone.0007304.g005
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Montanide ISA 720. The reactogenicity observed after immuni-
sation with AS02A formulation in our study was similar to what
was observed in clinical studies including prophylactic studies with
malaria, tuberculosis and HIV-1 vaccines and therapeutic studies
with vaccines against hepatitis B and tumour, where the vast
majority of local and systemic AEs (local pain and swelling,
headache, fatigue and GI) resolved within 24–48 h with no
sequelae [23]. Regarding Montanide ISA 720 formulations,
reactogenicity was lower in our study than previously described
in a review of nine trials encompassing 296 individuals receiving
Montanide ISA 720 adjuvanted vaccines by intramuscular route.
Mild to moderate local reactions occurred in half the volunteers
and severe local reactions in 4% of them, with rate and severity of
AE appearing to be antigen and dose dependent [24]. In the
current study, the reactogenicity associated with Montanide ISA
720 formulation was even lower than in our own observations with
synthetic malaria peptide MSP3 injected subcutaneously [21].
This route was chosen to obtain optimal conditions for
surveillance of reactivity. Simultaneously, subcutaneous injections
may increase the risk of induction of large local reactions in
comparison to intramuscular injections. The lower reactogenicity
induced with the Montanide formulation could also be explained
by the dose of adjuvant, 0.5 ml here against 1 ml in the MSP3
study, and the intrinsic character of the antigen/adjuvant mixture.
At least two mechanisms, humoral via antigen specific antibodies
and cellular via cytokine secreting specific T cells, may contribute
to protective pre-erythrocytic immunity and concur to clear
sporozoites before they reach the hepatocytes, to prevent liver
invasion and to kill infected hepatocytes [25]. PfCS102 vaccine
generated a strong antibody response directed against the C term
of CSP and recognizing as well the native protein at the surface of
the parasite. Comparison of the level of antigen specific antibody
responses between different trials based on CSP vaccine is difficult
in the absence of comparison of sporozoite antibody titers. The
highest levels of IFAT response were generated after 3
immunizations with PfCS102 formulated with AS02A. These
anti-sporozoite responses were at least equivalent to those obtained
in protected individuals immunized with RTS,S/AS02A, a Pf CSP
based malaria vaccine containing the sequence of PfCS102
[22,26]. In these volunteers, the presence of opsonizing antibodies
Table 4. Analysis of IFN-c producing CD4+ and CD8+ T cell
responses based on the dose of peptide per injection or the
adjuvant used.
Dose of PfCS102 (mg)
10 30 100 all dose levels
CD4+
Montanide ISA 720 3/3 (100%) 2/4 (50%) 3/5 (60%) 8/12 (67%)
AS02A 2/3 (67%) 3/3 (100%) 3/4 (75%) 8/10 (80%)
Total 5/6 (83%) 5/7 (71%) 6/9 (67%) 16/22 (73%)
CD8+
Montanide ISA 720 3/3 (100%) 3/4 (75%) 4/5 (80%) 10/12 (83%)
AS02A 2/3 (67%) 2/3 (67%) 2/4 (50%) 6/10 (60%)
Total 5/6 (83%) 5/7 (71%) 6/9 (67%) 16/22 (73%)
Values indicate numbers of volunteers presenting an individual increase in frequency
of IFN-c secreting PfCS102 specific CD4+ or CD8+ T cells, i.e. with an induced fre-
quency above the mean + 95% confidence interval of the pre-immune specific
responses in the 22 HLA-A2 and/or HLA-A3 volunteers and a delta above 0.02%.
doi:10.1371/journal.pone.0007304.t004
Figure 6. Time-course of individual frequencies of PfCS102
specific T cells. Frequencies were evaluated by intracellular cytokine
staining (ICS) using the PBMC of HLA-A2 and/or HLA-A3 volunteers.
Results are expressed as percentage of IFN-c positive cells upon PfCS
stimulation in the selected cell population: A, CD4+ cells; B, CD8+ cells;
C, CD3+CD8+ T cells (CD162/562, CTL, and CD16+/56+, NKT cells) in 8
responders. Dotted lines represent baseline. Statistical analysis was
based on Wilcoxon’s test with p,0.05 as the limit of significance.
Arrows indicate the times of vaccination.
doi:10.1371/journal.pone.0007304.g006
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facilitating the uptake of sporozoites by monocytes and/or
macrophages was demonstrated and proposed as a mechanism
of protection [27]. Nevertheless, this protection was not associated
with the recognition of a particular region of the CSP, since anti-
CSP repeat and anti-C terminal antibodies where both induced.
The intensity of the response to the CSP repeat, a dominant B cell
epitope, was correlated with protection but probably not sufficient
to induce it [28]. The protective activity of antibodies directed
against the C-term of PfCS in absence of anti-CSP repeat remains
to be determined.
As another mechanism, protection against natural and
artificial sporozoite exposition in vaccinated individuals has
been correlated with IFN-c producing CSP specific CD4+ T cells
[29,30]. In this study, high IFN-c production and proliferation by
specific CD4+ T cells were induced as assessed in 6-day
stimulation assay, particularly in AS02A groups. This Th1
response was accompanied by a low antigen specific production
of IL-10, which correlated with IFN-c production and may be
related to anti-inflammatory self-regulation mechanisms. In-
creased frequencies of CSP specific CD8+ lymphocytes were also
demonstrated in protected individuals after immunization with
RTS/S [30]. Using the same protocol as Sun et al., from 22
evaluated volunteers selected on their MHC-I, 8 clearly up-
regulated their frequencies of PfCS102 specific CD8+ cells with
vaccination. IFN-c producing NK marker bearing CD8+ cells
accounted for half of the total response in 5 out of these
responders. Whether these cells directly or indirectly responded
to PfCS peptides is not known. Nevertheless, the 5 volunteers
with partial NK responses showed a low but significant increase
in their frequencies of PfCS102 specific CD3+CD8+ T lympho-
cytes. The presence of peptide activated NK and NKT
lymphocytes induced with vaccination is not per se prejudicial
since these cells are clearly known for their abundance in the
liver, for their immediate and high production of cytokines upon
activation inducing the recruitment and activation of immune
cells. In particular, in mice, NK cells are required at the pre-
erythrocytic stage for the induction of CD8+ T cells necessary for
protective immunity against malaria [31].
In the present study, the range of PfCS specific CD8+
responses was moderate and CD8+ T cell cultured ELISPOT
did not appear sufficiently sensitive to detect responders with
PfCS specific IFN-c producing CD8+ T cells in comparison to
ICS (1/14 and 5/22 respectively). The responses we detected
were restricted to two HLA-A2 and two HLA-A3 epitopes. The
use in the assay of overlapping 15-mer peptides covering all the
PfCS102 sequence should have overcome the problem of genetic
restriction and possibly increased the level of responses. Despite
the restrictive conditions of the current analysis, we nonetheless
detected 16/22 (73%) individuals with enhanced CD8+ specific
responses, a frequency similar to that observed in our initial
study, where after 3 immunizations with a GLP PfCS102,
increase in CD8+ specific T cells was detectable in 5 out of 8
HLA-A2 volunteers [20].
In our initial study, after the 3rd vaccination with 300 mg of
GLP peptide, we observed a decrease in humoral and CMI
responses, which was interpreted as potential evidence of
tolerization as a consequence of high antigen dose. In the present
study, peptide doses were lowered to 10, 30 and 100 mg to avoid
this phenomenon. Indeed, immune responses did not decrease
after the 3rd injection. However there was no boost effect of this 3rd
dose. This was despite a sufficiently large interval of 4 months
between the 2nd and the 3rd injections designed precisely to avoid
induction of tolerance. We can thus conclude that the immune
response had reached its plateau with the peptides and adjuvants
used in this study. However, we cannot exclude an interest for the
3rd injection in the maintenance of the immune responses at Day
360.
Generalizibility
This Phase I study is limited in size and not powered for
generalizibility to the target population. Despite this fact, the safety
profile and the immunogenicity of the peptide formulations are
indicative and valuable for the choice of the dose of peptide and
the adjuvant for future development of a PfCS102 based vaccine
as well as other peptide based vaccines.
Overall evidence
In conclusion, PfCS102 peptide was highly immunogenic and
the large array of induced immune effectors (B cells, Th1 CD4+
and CD8+ T cells, and furthermore NK cells) suggested potential
for efficacy and long-term persistence of disease control.
Considering that the two adjuvant formulations were well
tolerated and safe, that the highest antibody and IFN-c responses
were induced with AS02A formulations, that doses of 30 mg and
100 mg of peptide induced similar responses, two or three
immunizations with a dose of 30 mg of PfCS102 formulated
preferentially with AS02A seem the most appropriate choice for
future clinical challenge studies.
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